Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Merck & Company (MRK) Stock Price & Analysis
11,277 Followers
MRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$97.81 - $133.10
Previous Close$128.66
Volume2.77M
Average Volume (3M)8.25M
Market Cap
$332.08B
Enterprise Value$354.53B
Total Cash (Recent Filing)$5.62B
Total Debt (Recent Filing)$34.22B
Price to Earnings (P/E)143.2
Beta0.22
Next Earnings
Jul 30, 2024EPS Estimate
$2.13Last Dividend Ex-Date
Mar 14, 2024Dividend Yield2.33%
Share Statistics
EPS (TTM)0.90
Shares Outstanding2,532,806,307
10 Day Avg. Volume6,837,102
30 Day Avg. Volume8,246,216
Standard Deviation0.06
R-Squared0.12
Alpha0.00938
Financial Highlights & Ratios
Price to Book (P/B)204.48
Price to Sales (P/S)20.76
Price to Cash Flow (P/CF)26.70
P/FCF Ratio33.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.77
Enterprise Value/Gross Profit8.06
Enterprise Value/Ebitda45.15
Forecast
1Y Price Target
$139.54Price Target Upside6.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsV940 (mRNA-4157) combo with Pembro demonstrated a significant reduction in the risk of recurrence or death and distant metastasis in melanoma patients, promising improved treatment outcomes.
Financial PerformanceMerck's first quarter revenue surpassed consensus estimates, and the company showed confidence in its financial future by raising revenue and non-GAAP EPS guidance.
Product Portfolio DiversificationMerck's strategic investment in R&D and the recent approval of Sotatercept signal strong potential for revenue growth and a move towards a diversified product portfolio.
Bears Say
Clinical Trial OutcomesThe Phase 3 KeyVibe-010 trial for high-risk melanoma was discontinued due to not meeting the pre-specified futility criteria, highlighting a lack of efficacy.
Drug PerformanceMerck's Bridion could underperform as U.S. sales strength is potentially offset by decreasing international sales and anticipated greater market erosion in Japan.
Pipeline AdjustmentsMerck's significant reduction in their oncology pipeline, including the elimination of various indications and treatments, could signal strategic setbacks or lack of progress.
---
Ownership Overview
0.16% Insiders
21.82% Mutual Funds
32.99% Other Institutional Investors
45.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $97.81 and its highest was $133.10 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 30, 2024 which is in 76 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 25, 2024. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.886 by $0.184.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.33%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $2.13.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,532,806,400 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.07 in its last earnings report, beating expectations of $1.886. Following the earnings report the stock price went up 2.929%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 1B.
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.54 (6.43% Upside)
$139.54 (6.43% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 93%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 744.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $34.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.83%
12-Months-Change
Fundamentals
Return on Equity
5.29%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q1 2024
0:00 / 0:00
---
MRK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$139.54
▲(6.43% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+17.07%
reiterated a buy rating 21 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +17.07% per trade.
---